Literature DB >> 25037253

Epidemiology of severe drug hypersensitivity.

Roni P Dodiuk-Gad, Philip M Laws, Neil H Shear1.   

Abstract

Epidemiological studies of severe drug hypersensitivities are important to understanding the morbidity and mortality of this heterogeneous group of disorders. These insights also allow greater identification of at-risk patient groups. However, epidemiological studies of drug hypersensitivity reactions are challenging due to the variable diagnostic criteria applied and incomplete data sets studied. We review the epidemiology of severe drug hypersensitivity reactions with a particular focus on severe cutaneous adverse reactions (SCARs). SCAR diseases include: Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash eosinophilia and systemic symptoms, serum-sickness-like reaction and acute generalized exanthematous pustulosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25037253     DOI: 10.12788/j.sder.0057

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN: 1085-5629


  9 in total

Review 1.  Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.

Authors:  S Shahzad Mustafa; David Ostrov; Daniel Yerly
Journal:  Curr Allergy Asthma Rep       Date:  2018-03-24       Impact factor: 4.806

2.  Demographic and clinical characteristics of patients with serum sickness-like reaction.

Authors:  Alaaddin Yorulmaz; Fatih Akın; Ahmet Sert; Mehmet Akif Ağır; Rıza Yılmaz; Şükrü Arslan
Journal:  Clin Rheumatol       Date:  2017-08-09       Impact factor: 2.980

3.  Epidemiology of drug hypersensitivity reactions using 6-year national health insurance claim data from Korea.

Authors:  JaeEun Han; Young-Min Ye; Sukhyang Lee
Journal:  Int J Clin Pharm       Date:  2018-04-02

Review 4.  SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.

Authors:  Katie D White; Riichiro Abe; Michael Ardern-Jones; Thomas Beachkofsky; Charles Bouchard; Bruce Carleton; James Chodosh; Ricardo Cibotti; Robert Davis; Joshua C Denny; Roni P Dodiuk-Gad; Elizabeth N Ergen; Jennifer L Goldman; James H Holmes; Shuen-Iu Hung; Mario E Lacouture; Rannakoe J Lehloenya; Simon Mallal; Teri A Manolio; Robert G Micheletti; Caroline M Mitchell; Maja Mockenhaupt; David A Ostrov; Rebecca Pavlos; Munir Pirmohamed; Elena Pope; Alec Redwood; Misha Rosenbach; Michael D Rosenblum; Jean-Claude Roujeau; Arturo P Saavedra; Hajirah N Saeed; Jeffery P Struewing; Hirohiko Sueki; Chonlaphat Sukasem; Cynthia Sung; Jason A Trubiano; Jessica Weintraub; Lisa M Wheatley; Kristina B Williams; Brandon Worley; Wen-Hung Chung; Neil H Shear; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2018 Jan - Feb

Review 5.  Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice.

Authors:  Jonathan Grant Peter; Rannakoe Lehloenya; Sipho Dlamini; Kimberly Risma; Katie D White; Katherine C Konvinse; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2017 May - Jun

6.  Immediate and non-immediate allergic reactions to amoxicillin present a diagnostic dilemma: a case series.

Authors:  Caroline Weisser; Moshe Ben-Shoshan
Journal:  J Med Case Rep       Date:  2016-01-18

7.  An Interesting Case of Carbamazepine-Induced Stevens-Johnson Syndrome.

Authors:  Josiah Tatenda Masuka; Garikai Muzopambwa; Star Khoza; Dixon Chibanda
Journal:  Drug Saf Case Rep       Date:  2018-12-10

8.  Stevens Johnson Syndrome and Toxic Epidermal Necrolysis: Maternal and Foetal Outcomes in Twenty-Two Consecutive Pregnant HIV Infected Women.

Authors:  Lauren Knight; Gail Todd; Rudzani Muloiwa; Mushi Matjila; Rannakoe J Lehloenya
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

9.  Use of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)-(Equine) (BAT®) in Clinical Study Subjects and Patients: A 15-Year Systematic Safety Review.

Authors:  Geraldine S Parrera; Hugo Astacio; Priya Tunga; Deborah M Anderson; Christine L Hall; Jason S Richardson
Journal:  Toxins (Basel)       Date:  2021-12-27       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.